SCHEMBL14026511

SCHEMBL14026511

Cc1cc(Nc2cc(Cl)nc(Cl)n2)[nH]n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PAK4 O96013 3/20 0.38
PLK4 O00444 1/20 0.38
MAPT P10636 4/20 0.34
GAA P10253 3/20 0.34
GSK3B P49841 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
POLB P06746 1/20 0.34
AURKA O14965 1/20 0.34
DAPK3 O43293 1/20 0.34
JAK2 O60674 1/20 0.34
ABL1 P00519 1/20 0.34
LCK P06239 1/20 0.34
FYN P06241 1/20 0.34
CSF1R P07333 1/20 0.34
RET P07949 1/20 0.34
IGF1R P08069 1/20 0.34
PDGFRB P09619 1/20 0.34
FGFR1 P11362 1/20 0.34
FLT1 P17948 1/20 0.34
LTK P29376 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30702750 1.00 PAK4 (0.38) PAK4PLK4MAPTGAAGSK3B
SCHEMBL19796066 0.88 MAPT (0.41) PAK4PLK4MAPTSMN1; SMN2POLB
SCHEMBL91111 0.84 GSK3B (0.35) PAK4PLK4MAPTGAAGSK3B
SCHEMBL61333 0.81 KMT2A (0.53) GAASMN1; SMN2POLBAURKAAURKB
SCHEMBL29155680 0.80 HSP90AA1 (0.38) PAK4PLK4MAPTKMT2ANPC1
SCHEMBL30702723 0.80 HSP90AA1 (0.38) PAK4PLK4MAPTKMT2ANPC1
SCHEMBL63682 0.79 AURKA (0.46) PAK4PLK4GSK3BSMN1; SMN2AURKA
SCHEMBL61956 0.79 GSK3B (0.32) PAK4MAPTGAAGSK3BSMN1; SMN2
SCHEMBL786647 0.78 LMNA (0.55) GSK3BAURKAABL1LCKFYN
SCHEMBL2203730 0.78 MAPT (0.50) MAPTGAAGSK3BSMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117355508-A Heterocyclic derivative and application thereof in medicine 西藏海思科制药有限公司 2024-01-05 CN disclosed
WO-2022078305-A1 HETEROCYCLIC DERIVATIVE AND MEDICAL APPLICATION THEREOF 四川海思科制药有限公司 2022-04-21 WO disclosed
US-20080269266-A1 NOVEL COMPOUNDS 747 ASTRAZENECA AB (SE) 2008-10-30 US disclosed
US-20080269266-A1 NOVEL COMPOUNDS 747 ASTRAZENECA AB (SE) 2008-10-30 US disclosed
WO-2008117051-A1 S-6-METH0XY-2- (2- (3- (PYRIMID-2-YL) IS0XAZ0L-5-YL) PYRROLIDIN-1-YL) -4- (5-METHYL-IH-PYRAZOL-S-YLAMINO) PYRIMIDINE AND POLYMORPHIC FORMS THEREOF AS MODULATORS OF THE INSULIN-LIKE GROWTH ASTRAZENECA AB (SE) 2008-10-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269266-A1 NOVEL COMPOUNDS 747 UGT2B7, UGT1A7, CYP3A7 PAK4 802/4885PLK4 1613/4885MAPT 2063/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.